Monoclonal Antibodies Specific for SARS-CoV-2 Spike Protein Suitable for Multiple Applications for Current Variants of Concern
Mahali S. Morgan, Kexin Yan, Thuy T. Le, Ryan Johnston, Alberto A. Amarilla, David A. Muller, Christopher L. D. McMillan, Naphak Modhiran, Daniel Watterson, James R. Potter, Julian D. J. Sng, Mary Lor, Devina Paramitha, Ariel Isaacs, Alexander A. Khromykh, Roy A. Hall, Andreas Suhrbier, Daniel J. Rawle, Jody Hobson‐Peters
Abstract
The global coronavirus disease 2019 (COVID-19) pandemic caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has spawned an ongoing demand for new research reagents and interventions. Herein we describe a panel of monoclonal antibodies raised against SARS-CoV-2. One antibody showed excellent utility for immunohistochemistry, clearly staining infected cells in formalin-fixed and paraffin embedded lungs and brains of mice infected with the original and the omicron variants of SARS-CoV-2. We demonstrate the reactivity to multiple variants of concern using ELISAs and describe the use of the antibodies in indirect immunofluorescence assays, Western blots, and rapid antigen tests. Finally, we illustrate the ability of two antibodies to reduce significantly viral tissue titers in K18-hACE2 transgenic mice infected with the original and an omicron isolate of SARS-CoV-2.